unresectable advanced or metastatic cancer
Oncology · 2025–2025
2decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab; ipilimumab Unresectable advanced or metastatic cancer. The proposed multi-indication listing would consolidate multiple cancer indications including melanoma, NSCLC, RCC,… | Sep 2025 | Deferred | input received |
| pembrolizumab Advanced or metastatic cancers. Expanded listing to include multiple tumor types and treatment settings including rare cancers, retreatment, and use beyond… | Dec 2025 | Recommended with restriction | no section in document |
What the PBS pays
$939M in government benefit over 2024–25, across 99,084 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| nivolumab; ipilimumab | $199M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.